U.S. FDA Approves Zongertinib

The U.S. Food and Drug Administration approved zongertinib (Hernexeos) as a first-line treatment for a rare form of lung cancer. The drug targets specific mutations in non-squamous non-small cell lung cancer.

Zongertinib and Non-Small Cell Lung Cancer:

Dimension	Key Details
Zongertinib	Zongertinib is marketed under the name Hernexeos
Drug Type	Zongertinib is a tyrosine kinase inhibitor used as targeted cancer therapy
Tyrosine Kinase Function	Tyrosine kinase is a protein that controls cell growth and function by transmitting signals inside cells
Mechanism of Action	Tyrosine kinase inhibitors block tyrosine kinase enzymes thereby preventing cancer cells from growing and dividing
Target Condition	Applies to adults with advanced non squamous non small cell lung cancer with HER2 ERBB2 tyrosine kinase domain mutations
Approval Authority	Approved by the United States Food and Drug Administration
Approval Status	Earlier approved for patients whose cancer progressed despite prior treatment and now authorised as first line therapy for untreated patients
Clinical Result	~ 76% of untreated patients showed tumour reduction compared to 30 to 45% with existing standard treatment
Non Small Cell Lung Cancer	Most common form of lung cancer and generally grows and spreads more slowly than small cell lung cancer
NSCLC Types	Adenocarcinoma squamous cell carcinoma and large cell carcinoma
Symptoms	Persistent cough coughing up blood chest pain breathlessness hoarseness weight loss and sometimes bone pain or neurological problems
Risk Factors	Tobacco smoking and exposure to asbestos radon arsenic chromium nickel ionising radiation and air pollution
Disease Stages	Early stages I to III mainly limited to lung or nearby areas while Stage IV indicates spread to distant organs such as brain bones or liver
Treatment Approaches	Includes surgery chemotherapy radiation therapy targeted therapy immunotherapy and combination therapy depending on stage and patient condition